Quest Diagnostics Inc vs Invesco Solar ETF — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Invesco Solar ETF trades at $52.39. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while Invesco Solar ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| DGX | TAN | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Sector/Thematic |
52-Week High | $238.50 | $73.95 |
52-Week Low | $173.49 | $36.62 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
TAN (Invesco Solar ETF) trades at $52.33, up 0.91% with a bearish technical signal from moving averages. The solar ETF faces mixed sentiment as recent Trump administration tariffs on polysilicon imports provide potential tailwinds for U.S. solar manufacturers while regulatory uncertainty and high volatility (beta 1.41) persist. Technical indicators show neutral oscillators with key support at $50 and resistance at $53.
The solar sector outlook is bifurcated between policy-driven opportunities and fundamental challenges. Tariff protections could benefit domestic manufacturers, but high expense ratios (0.7%) and residential solar demand concerns create headwinds. Investment appeal depends on policy stability and the sector's ability to capitalize on growing energy demand from data centers and AI infrastructure.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →